Cosmos Health Launches Clinically Studied Curcumin Supplement Cur18 in the US

Next-gen formulation delivers up to 39x higher bioavailability than standard curcumin extracts

Apr. 17, 2026 at 6:08pm

Got story updates? Submit your updates here. ›

An extreme close-up X-ray image of the intricate internal structure of a turmeric root, appearing as a ghostly, glowing network of lines and shapes against a dark background, conceptually representing the advanced science behind the new Cur18 curcumin supplement.A revealing X-ray view of the internal structure of the turmeric root, the key ingredient in Cosmos Health's new Cur18 supplement formulation.Chicago Today

Cosmos Health Inc. announced the planned Q2 2026 U.S. launch of Cur18, a next-generation curcumin supplement designed to address the poor bioavailability of conventional curcumin formulations. Cur18 is based on a turmeric-derived, clinically studied extract that has demonstrated up to 39x higher free curcumin bioavailability compared to standard 95% curcuminoid extracts in published research.

Why it matters

The U.S. turmeric supplement market is a well-established, multi-billion dollar category driven by consumer demand for curcumin's antioxidant and anti-inflammatory benefits. However, the premium, high-performance segment remains underpenetrated, creating an opportunity for differentiated formulations like Cur18 that can deliver significantly enhanced bioavailability.

The details

Cur18 utilizes an advanced formulation approach that preserves the native turmeric matrix, including curcuminoids, essential oils, and polar resins, to support improved absorption and bioavailability. In addition to the bioavailability advantage, Cur18 is described as self-affirmed GRAS, supports joint health based on clinical research, and is developed without synthetic bio-enhancers or black pepper extract.

  • Cosmos Health plans to launch Cur18 in the U.S. market in Q2 2026.

The players

Cosmos Health Inc.

A diversified, vertically integrated global healthcare group that owns a portfolio of proprietary pharmaceutical and nutraceutical brands.

Greg Siokas

CEO of Cosmos Health, who stated that Cur18 represents a new standard in curcumin supplementation with its clinically studied, patented formulation designed to enhance bioavailability.

Got photos? Submit your photos here. ›

What they’re saying

“Cur18 ™ represents a new standard in curcumin supplementation. For decades, consumers have been told that turmeric is powerful - but conventional formulations have been limited by poor absorption. With Cur18 ™, we are introducing a clinically studied, patented formulation designed to enhance bioavailability and deliver meaningful results.”

— Greg Siokas, CEO of Cosmos Health

What’s next

Cosmos Health plans to make Cur18 available through multiple channels targeting the U.S. nutraceutical market, including e-commerce platforms, direct-to-consumer channels, health and specialty retail locations, and healthcare practitioner networks.

The takeaway

Cosmos Health's launch of Cur18, a clinically studied curcumin supplement with significantly enhanced bioavailability, represents an opportunity to differentiate in the growing U.S. turmeric supplement market by addressing a key limitation of conventional formulations.